Brain injury is a common cause for physical and emotional effects to the large number of populations. Moreover, glioblastoma is the tumor in brain with no possible treatment leading to death. The blood-brain barrier's makes the treatment more difficult by preventing the drugs to reach central nervous system. Paclitaxel (PTX) encapsulated Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), PTX-PLGA-NPs were developed using emulsification method. The PTX-PLGA-NPs were characterized using Malvern Zetasizer and Scanning Electron Microscopy and were evaluated for their cytotoxicity in U87MG cells. PTX-PLGA-NPs were prepared using single emulsion method having size of 154 ± 22.19 nm with zeta potential of -23.7 mV. The PTX-PLGA-NPs were spherical in shape and have dose dependent cytotoxicity on U87MG cells. The PTX was released from the particles with initial burst release followed by sustained release pattern. The biodistribution was studied in mice with glioblastoma model using 125I radiolabeled PTX-PLGA-NPs and anti-glioblastoma was studied with PTX-PLGA-NPs. The biodistribution studies revealed PTX-PLGA-NPs after intranasal administration resulted in higher in vivo uptake with high anti-glioblastoma efficacy. The results suggest that PTX-PLGA-NPs administered through intranasal route have potential in the treatment of glioblastoma.

中文翻译：

---

鼻内递送紫杉醇包裹的纳米颗粒治疗胶质母细胞瘤引起的脑损伤

脑损伤是对大量人群造成身体和情绪影响的常见原因。此外，胶质母细胞瘤是大脑中的肿瘤，没有可能导致死亡的治疗方法。血脑屏障阻止药物到达中枢神经系统，从而使治疗变得更加困难。紫杉醇（PTX）包封的聚（乳酸-乙醇酸共聚物）（PLGA）纳米颗粒（NPs）、PTX-PLGA-NPs是使用乳化方法开发的。PTX-PLGA-NPs 使用 Malvern Zetasizer 和扫描电子显微镜进行表征，并评估它们在 U87MG 细胞中的细胞毒性。PTX-PLGA-NPs 使用单乳液法制备，尺寸为 154±22.19 nm，zeta 电位为 -23.7 mV。PTX-PLGA-NPs 呈球形，对 U87MG 细胞具有剂量依赖性细胞毒性。PTX 从颗粒中释放出来，最初是突然释放，然后是持续释放模式。使用 125 I 放射性标记的 PTX-PLGA-NPs 研究了胶质母细胞瘤模型小鼠的生物分布，并使用 PTX-PLGA-NPs 研究了抗胶质母细胞瘤。生物分布研究表明，鼻内给药后 PTX-PLGA-NPs 导致更高的体内摄取，具有高抗胶质母细胞瘤功效。结果表明，通过鼻内途径给药的 PTX-PLGA-NPs 具有治疗胶质母细胞瘤的潜力。生物分布研究表明，鼻内给药后 PTX-PLGA-NPs 导致更高的体内摄取，具有高抗胶质母细胞瘤功效。结果表明，通过鼻内途径给药的 PTX-PLGA-NPs 具有治疗胶质母细胞瘤的潜力。生物分布研究表明，鼻内给药后 PTX-PLGA-NPs 导致更高的体内摄取，具有高抗胶质母细胞瘤功效。结果表明，通过鼻内途径给药的 PTX-PLGA-NPs 具有治疗胶质母细胞瘤的潜力。